Northwestern Mutual Wealth Management Co. Has $4.27 Million Stock Holdings in Edwards Lifesciences Corporation $EW

Northwestern Mutual Wealth Management Co. decreased its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 18.0% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 47,155 shares of the medical research company’s stock after selling 10,362 shares during the quarter. Northwestern Mutual Wealth Management Co.’s holdings in Edwards Lifesciences were worth $4,266,000 as of its most recent filing with the Securities and Exchange Commission.

Several other large investors have also recently bought and sold shares of EW. Pin Oak Investment Advisors Inc. purchased a new position in Edwards Lifesciences during the 2nd quarter valued at about $26,000. TrinityBridge Ltd acquired a new stake in shares of Edwards Lifesciences during the second quarter worth approximately $27,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $26,000. Hanson & Doremus Investment Management purchased a new position in Edwards Lifesciences during the first quarter valued at approximately $25,000. Finally, Kemnay Advisory Services Inc. acquired a new position in Edwards Lifesciences in the 4th quarter valued at approximately $27,000. 79.46% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In related news, VP Annette Brüls sold 2,644 shares of Edwards Lifesciences stock in a transaction on Friday, August 28th. The shares were sold at an average price of $89.98, for a total value of $237,907.12. Following the transaction, the vice president owned 17,984 shares in the company, valued at $1,618,200.32. This trade represents a 12.82% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Andrew M. Dahl sold 544 shares of the business’s stock in a transaction on Monday, August 31st. The stock was sold at an average price of $91.06, for a total transaction of $49,536.64. Following the transaction, the senior vice president directly owned 14,868 shares of the company’s stock, valued at approximately $1,353,880.08. This represents a 3.53% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last three months, insiders have sold 5,045 shares of company stock worth $457,749. 0.31% of the stock is owned by insiders.

Wall Street Analysts Forecast Growth

EW has been the subject of a number of research analyst reports. Truist Financial increased their target price on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the stock a “hold” rating in a research report on Thursday, July 16th. BTIG Research upped their price target on shares of Edwards Lifesciences from $100.00 to $110.00 and gave the stock a “buy” rating in a research note on Tuesday, June 30th. Citigroup increased their price objective on Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. JPMorgan Chase & Co. boosted their target price on Edwards Lifesciences from $100.00 to $105.00 and gave the company an “overweight” rating in a research note on Friday, July 24th. Finally, Royal Bank Of Canada upped their target price on Edwards Lifesciences from $100.00 to $110.00 and gave the stock an “outperform” rating in a research report on Monday, July 13th. Seventeen analysts have rated the stock with a Buy rating and six have assigned a Hold rating to the stock. According to MarketBeat.com, Edwards Lifesciences currently has an average rating of “Moderate Buy” and an average target price of $100.27.

Edwards Lifesciences Stock Down 1.0%

Shares of Edwards Lifesciences stock opened at $89.89 on Friday. The stock has a market capitalization of $51.76 billion, a P/E ratio of 51.66, a PEG ratio of 2.38 and a beta of 0.85. The company has a quick ratio of 3.77, a current ratio of 4.52 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average price of $89.74 and a two-hundred day moving average price of $85.46. Edwards Lifesciences Corporation has a 12-month low of $72.30 and a 12-month high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The company had revenue of $1.74 billion for the quarter, compared to the consensus estimate of $1.70 billion. During the same quarter last year, the company posted $0.67 earnings per share. The company’s revenue for the quarter was up 13.6% compared to the same quarter last year. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. Equities analysts expect that Edwards Lifesciences Corporation will post 3 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.